11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Reduced scar maturation and contractility lead to exaggerated left ventricular dilation after myocardial infarction in mice lacking AMPKα1.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cardiac fibroblasts (CF) are crucial in left ventricular (LV) healing and remodeling after myocardial infarction (MI). They are typically activated into myofibroblasts that express alpha-smooth muscle actin (α-SMA) microfilaments and contribute to the formation of contractile and mature collagen scars that minimize the adverse dilatation of infarcted areas. CF predominantly express the α1 catalytic subunit of AMP-activated protein kinase (AMPKα1), while AMPKα2 is the major catalytic isoform in cardiomyocytes. AMPKα2 is known to protect the heart by preserving the energy charge of cardiac myocytes during injury, but whether AMPKα1 interferes with maladaptative heart responses remains unexplored. In this study, we investigated the role of AMPKα1 in modulating LV dilatation and CF fibrosis during post-MI remodeling. AMPKα1 knockout (KO) and wild type (WT) mice were subjected to permanent ligation of the left anterior descending coronary artery. The absence of AMPKα1 was associated with increased CF proliferation in infarcted areas, while expression of the myodifferentiation marker α-SMA was decreased. Faulty maturation of myofibroblasts might derive from severe down-regulation of the non-canonical transforming growth factor-beta1/p38 mitogen-activated protein kinase (TGF-β1/p38 MAPK) pathway in KO infarcts. In addition, lysyl oxidase (LOX) protein expression was dramatically reduced in the scar of KO hearts. Although infarct size was similar in AMPK-KO and WT hearts subjected to MI, these changes resulted in compromised scar contractility, defective scar collagen maturation, and exacerbated adverse remodeling, as indicated by increased LV diastolic dimension 30days after MI. Our data genetically demonstrate the centrality of AMPKα1 in post-MI scar formation and highlight the specificity of this catalytic isoform in cardiac fibroblast/myofibroblast biology.

          Related collections

          Author and article information

          Journal
          J. Mol. Cell. Cardiol.
          Journal of molecular and cellular cardiology
          Elsevier BV
          1095-8584
          0022-2828
          Sep 2014
          : 74
          Affiliations
          [1 ] Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Université catholique de Louvain, Brussels, Belgium. Electronic address: Gauthier.noppe@uclouvain.be.
          [2 ] Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Université catholique de Louvain, Brussels, Belgium. Electronic address: cecile.dufeys@uclouvain.be.
          [3 ] Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Université catholique de Louvain, Brussels, Belgium. Electronic address: patricia.buchlin@uclouvain.be.
          [4 ] Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Université catholique de Louvain, Brussels, Belgium. Electronic address: nicolas.marquet@uclouvain.be.
          [5 ] Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Université catholique de Louvain, Brussels, Belgium. Electronic address: diego.castanares@uclouvain.be.
          [6 ] Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Université catholique de Louvain, Brussels, Belgium. Electronic address: magali.balteau@uclouvain.be.
          [7 ] Institut de Recherche Expérimentale et Clinique, Pôle de Pharmacologie et Thérapeutique, Université catholique de Louvain, Brussels, Belgium. Electronic address: nerea.hermida@uclouvain.be.
          [8 ] Institut de Recherche Expérimentale et Clinique, Pôle de Pharmacologie et Thérapeutique, Université catholique de Louvain, Brussels, Belgium. Electronic address: caroline.bouzin@uclouvain.be.
          [9 ] Institut de Recherche Expérimentale et Clinique, Pôle de Pharmacologie et Thérapeutique, Université catholique de Louvain, Brussels, Belgium. Electronic address: hrag.esfahani@uclouvain.be.
          [10 ] Institut Cochin, INSERM U1016, Paris, France; CNRS, UMR8104, Paris, France; Université Paris Descartes, Sorbonne, Paris Cité, France. Electronic address: benoit.viollet@inserm.fr.
          [11 ] Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Université catholique de Louvain, Brussels, Belgium. Electronic address: luc.bertrand@uclouvain.be.
          [12 ] Institut de Recherche Expérimentale et Clinique, Pôle de Pharmacologie et Thérapeutique, Université catholique de Louvain, Brussels, Belgium. Electronic address: jean-luc.balligand@uclouvain.be.
          [13 ] Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Université catholique de Louvain, Brussels, Belgium; Cardiology Division, Department of Cardiovascular Diseases, Cliniques Universitaires Saint-Luc, Brussels, Belgium. Electronic address: jean-louis.vanoverschelde@uclouvain.be.
          [14 ] Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Université catholique de Louvain, Brussels, Belgium; Cardiology Division, Department of Cardiovascular Diseases, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Cardiovascular Intensive Care, Department of Cardiovascular Diseases, Cliniques Universitaires Saint-Luc, Brussels, Belgium. Electronic address: christophe.beauloye@uclouvain.be.
          [15 ] Institut de Recherche Expérimentale et Clinique, Pôle de Recherche Cardiovasculaire, Université catholique de Louvain, Brussels, Belgium. Electronic address: sandrine.horman@uclouvain.be.
          Article
          S0022-2828(14)00147-3
          10.1016/j.yjmcc.2014.04.018
          24805196
          4bea0a35-e540-459e-9f05-75666898c009
          History

          Myodifferentiation,Cardiac fibroblast,Myocardial infarction,Scar maturation,AMPK

          Comments

          Comment on this article